Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

THIAMINE HCL

All products: not a benefit

Vitamin B1-ICN · DIN 00268631 · 50mg · tablet

Listed, not a benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health CanadaHealth Canada: not checked yet (expand to check)
StatusListed, not a benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada
Patient paysPatient pays: program not supplied; amount cannot be determined.
Health Canada: not checked yet (expand to check)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Vitamin B1-ICN · DIN 00268631 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: not checked yet (expand to check)
Check this DIN again

Vitamin B1-ICN: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada: not checked yet (expand to check) · Verify on the e-Formulary ↗ (DIN 00268631)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00268631). DIN 00268631: Vitamin B1-ICN Raw flags: dinStatus=E, notABenefit=Y, sec3=Y Item: 880800012; group id 884; item number 2125; lccId None; manufacturer id VAL Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; DIN status E, meaning unconfirmed Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00268631
Interchangeable products
Vitamin B1 · DIN 00610267 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00268631
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (88:08 Vitamin B) and how they are covered

Matched class: 88:08 Vitamin B

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: LEUCOVORIN CALCIUM Some products covered without a code (check the product listing): CYANOCOBALAMIN, FOLIC ACID 88:08 Vitamin B

CYANOCOBALAMIN

· 5 products · Listed, not a benefit (1), General benefit (4) · strengths: 1mg/mL · Inj Sol-10mL Pk

FOLIC ACID

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 5mg · Tab

LEUCOVORIN CALCIUM

· 4 products · General benefit · strengths: 5mg · Tab

NICOTINIC ACID

· 2 products · Listed, not a benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 88:08
Full class listing Related classes: 88:12 Vitamin C, 88:16 Vitamin D, 88:28 Multivitamins Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Vitamin B1-ICN: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026